This trial studies if pyridostigmine can help with constipation in people with Parkinson's Disease, as constipation can severely impact quality of life.
- Parkinson's Disease
1 Primary · 7 Secondary · Reporting Duration: 13-15 Weeks
0 Treatment Group
16 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How does this treatment rate in terms of its impact on the long-term health and wellbeing of those who receive it?
"This Phase 2 trial has some evidence of safety, so our team at Power assigned it a score of 2. Unfortunately, there is currently no data confirming its efficacy." - Anonymous Online Contributor
What is the maximum participant capacity for this clinical research endeavor?
"Affirmative. Clinicaltrials.gov confirms that this research is currently recruiting participants, having been first published on August 10th 2022 and updated most recently in October 2021. 16 individuals need to be recruited from 1 medical centre for the trial to continue." - Anonymous Online Contributor
Does this medical experiment have open enrollment at the moment?
"Confirmed. Clinicaltrials.gov contains data which suggests that this experiment is currently recruiting and began on August 10th 2022. The latest update was October 31st 2022, with a total 16 participants needed from one medical centre alone." - Anonymous Online Contributor